Compare SFM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | TVTX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 2013 | 2013 |
| Metric | SFM | TVTX |
|---|---|---|
| Price | $52.04 | $50.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $56.92 | ★ $73.43 |
| AVG Volume (30 Days) | ★ 4.2M | 2.1M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.60 | ★ 92.89 |
| EPS | ★ 4.30 | N/A |
| Revenue | ★ $8,806,159,000.00 | N/A |
| Revenue This Year | $5.96 | $55.96 |
| Revenue Next Year | $4.84 | $48.63 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $47.35 | $22.59 |
| 52 Week High | $94.89 | $68.73 |
| Indicator | SFM | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 44.19 |
| Support Level | $47.35 | $49.46 |
| Resistance Level | $87.91 | $54.43 |
| Average True Range (ATR) | 2.89 | 2.61 |
| MACD | -0.06 | 0.49 |
| Stochastic Oscillator | 23.75 | 70.30 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.